Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov1676610.25208/vdv16766REVIEWSОБЗОР ЛИТЕРАТУРЫResearch ArticleBiotechnology in dermatology: present and futureБиотехнологии в дерматовенерологии: настоящее и будущееhttps://orcid.org/0000-0002-7677-15448802-7325VlasovaAnna V.ВласоваАнна Васильевна
Russian Federation

MD, PhD

кандидат медицинских наук

avvla@mail.ruhttps://orcid.org/0000-0002-5756-27472613-8597MartynovAndrey A.МартыновАндрей Александрович
Russian Federation

MD, Dr. Sci. (Med.), Professor

доктор медицинских наук, профессор

aamart@mail.ruhttps://orcid.org/0009-0000-5377-1739MartynovaMaria A.МартыноваМария Андреевна
Israel

Student

студентка

manmartyn@gmail.comI.M. Sechenov First Moscow State Medical University (Sechenov University)Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)State Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологииTel Aviv UniversityТель-Авивский университет1608202426082024100431412602202412072024Copyright ©; 2024, Vlasova A.V., Martynov A.A., Martynova M.A.Copyright ©; 2024, Власова А.В., Мартынов А.А., Мартынова М.А.2024Vlasova A.V., Martynov A.A., Martynova M.A.Власова А.В., Мартынов А.А., Мартынова М.А.https://creativecommons.org/licenses/by-nc/4.0https://vestnikdv.ru/jour/article/view/16766

One of the fastest disciplinary measures 21 century is biotechnology, which in the last decade has become a powerful tool and assistant in the diagnosis, prognosis and elimination of various diseases. The article is devoted to a description of the following sections of medical biotechnologies used in dermatology, such as gene therapy, molecular diagnostics, pharmacogenomics and genetic (tissue) engineering. The article creates the potential for the use of biotechnology in dermatology, which remains the main hope of dermatology patients and dermatologists.

Одним из самых стремительно развивающихся научных направлений в настоящее время являются биотехнологии, которые в последнее десятилетие стали мощным оружием и помощником в диагностике, прогнозе и лечении ряда заболеваний, в том числе болезней кожи. В статье подробно освещены ключевые подразделы медицинских биотехнологий, применямых в дерматовенерологии, таких как генная терапия, молекулярная диагностика, фармакогеномика и генная (тканевая) инженерия. Подчеркивается потенциал применения биотехнологий в дерматовенерологии, который остается главной надеждой больных, страдающих заболеваниями кожи и подкожной клетчатки, а также врачей-дерматовенерологов.

biotechnologydermatovenerologygene therapymolecular diagnosticspharmacogenomicsgenetic engineeringбиотехнологиидерматовенерологиягенная терапиямолекулярная диагностикафармакогеномикагенная инженерияI.M. Sechenov First Moscow State Medical University (Sechenov University); State Research Center of Dermatovenereology and Cosmetology; Tel Aviv UniversityПервый Московский государственный медицинский университет имени И.М. Сеченова; Государственный научный центр дерматовенерологии и косметологии; Тель-Авивский университетPham PV. Medical Biotechnology: Techniques and Applications. In: Omics Technologies and Bio-engineering: Towards Improving Quality of Life. Academic Press; 2018. P. 449–69. doi: 10.1016/B978-0-12-804659-3.00019-1Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. doi: 10.1038/s41392-021-00487-6Alnasser SM. Review on mechanistic strategy of gene therapy in the treatment of disease. Gene. 2021;769:145246. doi: 10.1016/j.gene.2020.145246Guide SV, Gonzalez ME, Bağcı IS, Agostini B, Chen H, Feeney G, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022;387(24):2211–2219. doi: 10.1056/nejmoa2206663Dhillon S. Beremagene Geperpavec: First Approval. Drugs. 2023;83(12):1131–1135. doi: 10.1007/s40265-023-01921-5Krystal biotech. New Data on B-VEC and Dystrophic Epidermolysis Bullosa (DEB) Presented at the DEBRA International Conference; 2021.Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): An intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel). 2021;13(6):1383. doi: 10.3390/cancers13061383Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors. Hum Gene Ther. 2006;17(3):253–263. doi: 10.1089/hum.2006.17.253Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346–358. doi: 10.1038/nrg1066Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther. 2004;11(Suppl 1):S10–7. doi: 10.1038/sj.gt.3302364Midoux P, Pichon C, Yaouanc JJ, Jaffrès PA. Chemical vectors for gene delivery: A current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol. 2009;157(2):166–178. doi: 10.1111/j.1476-5381.2009.00288.xWang M, Marepally SK, Vemula PK, Xu C. Inorganic Nanoparticles for Transdermal Drug Delivery and Topical Application. In: Nanoscience in Dermatology. Elsevier Inc.; 2016. P. 57–72. doi: 10.1016/B978-0-12-802926-8.00005-7Siu KS, Chen D, Zheng X, Zhang X, Johnston N, Liu Y, et al. Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma. Biomaterials. 2014;35(10):3435–3442. doi: 10.1016/j.biomaterials.2013.12.079Desai PR, Marepally S, Patel AR, Voshavar C, Chaudhuri A, Singh M. Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release. 2013;170(1):51–63. doi: 10.1016/j.jconrel.2013.04.021Bracke S, Carretero M, Guerrero-Aspizua S, Desmet E, Illera N, Navarro M, et al. Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: Development of siRNA SECosome-based novel therapies. Exp Dermatol. 2014;23(3):199–201. doi: 10.1111/exd.12321Kim ST, Lee KM, Park HJ, Jin SE, Ahn WS, Kim CK. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J Gene Med. 2009;11(1):26–37. doi: 10.1002/jgm.1268Li J, Li X, Zhang Y, Zhou XK, Yang HS, Chen XC, et al. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. J Gene Med. 2010;12(6):481–490. doi: 10.1002/jgm.1459Lewandowski KT, Thiede R, Guido N, Daniel WL, Kang R, Guerrero-Zayas MI, et al. Topically Delivered Tumor Necrosis Factor-α–Targeted Gene Regulation for Psoriasis. J Invest Dermatol. 2017;137(9):2027–2030. doi: 10.1016/j.jid.2017.04.027Zheng D, Giljohann DA, Chen DL, Massich MD, Wang XQ, Iordanov H, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Nat Acad Sci U S A. 2012;109(30):11975–11980. doi: 10.1073/pnas.1118425109/-/DCSupplementalRanderia PS, Seeger MA, Wang XQ, Wilson H, Shipp D, Mirkin CA, et al. siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown. Proc Natl Acad Sci U S A. 2015;112(18):5573–5578. doi: 10.1073/pnas.1505951112Yi X, Zhao G, Zhang H, Guan D, Meng R, Zhang Y, et al. MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther. 2011;19(2):362–371. doi: 10.1038/mt.2010.263Heydari Z, Peshkova M, Gonen ZB, Coretchi I, Eken A, Yay AH, et al. EVs vs. EVs: MSCs and Tregs as a source of invisible possibilities. J Mol Med (Berl). 2023;101(1–2):51–63. doi: 10.1007/s00109-022-02276-2Lo AC, Feldman SR. Polymerase chain reaction: Basic concepts and clinical applications in dermatology. J Am Acad Dermatol. 1994;30(2):250–260. doi: 10.1016/S0190-9622(94)70025-7Mania-Pramanik J, Donde UM, Maitra A. Use of polymerase chain reaction (PCR) for detection of Chlamydia trachomatis infection in cervical swab samples. Indian J Dermatol Venereol Leprol. 2001;67(5):246–250.Liu H, Rodes B, Chen CY, Steiner B. New tests for syphilis: Rational design of a PCR method for detection of Treponema pallidum in clinical specimens using unique regions of the DNA polymerase I gene. J Clin Microbiol. 2001;39(5):1941–1946. doi: 10.1128/JCM.39.5.1941-1946.2001Shafie MH, Antony Dass M, Ahmad Shaberi HS, Zafarina Z. Screening and confirmation tests for SARS-CoV-2: benefits and drawbacks. Beni Suef Univ J Basic Appl Sci. 2023;12(1):6. doi: 10.1186/s43088-023-00342-3D’Amico F, Skarmoutsou E, Stivala F. State of the art in antigen retrieval for immunohistochemistry. J Immunol Methods. 2009;341(1–2):1–18. doi: 10.1016/j.jim.2008.11.007Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289–298. doi: 10.1007/978-1-4939-8935-5_25Palit A, Inamadar AC. Immunohistochemistry: Relevance in dermatology. Indian J Dermatol. 2011;56(6):629–640. doi: 10.4103/0019-5154.91818Chatterjee D, Bhattacharjee R. Immunohistochemistry in dermatopathology and its relevance in clinical practice. Indian Dermatol Online J. 2018;9(4):234–244. doi: 10.4103/idoj.idoj_8_18Esposito R. What are the different detection methods for IHC? Enzo Life Sciences; 2019.King AD, Deirawan H, Klein PA, Dasgeb B, Dumur CI, Mehregan DR. Next-generation sequencing in dermatology. Front Med (Lausanne). 2023;10:2128404. doi: 10.3389/fmed.2023.1218404Qin D. Next-generation sequencing and its clinical application. Cancer Biol Med. 2019;16(1):4–10. doi: 10.20892/j.issn.2095-3941.2018.0055Sarig O, Sprecher E. The Molecular Revolution in Cutaneous Biology: Era of Next-Generation Sequencing. J Invest Dermatol. 2017;137(5):е79–е82. doi: 10.1016/j.jid.2016.02.818Gonzalez D, Fearfield L, Nathan P, Tanière P, Wallace A, Brown E, et al. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: Recommendations from an expert panel. Br J Dermatol. 2013;168(4):700–707. doi: 10.1111/bjd.12248Todd P, Samaratunga IR, Pembroke A. Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy. Clin Exp Dermatol. 1994;19(3):217–218. doi: 10.1111/j.1365-2230.1994.tb01168.xIznardo H, Roé E, Serra-Baldrich E, Puig L. Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics. 2023;15(2):385. doi: 10.3390/pharmaceutics15020385Diasio RB, Offer SM. Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy. Cancers (Basel). 2022;14(13):3207. doi: 10.3390/cancers14133207Mitra D, Chopra A, Saraswat N, Mitra B, Talukdar K, Agarwal R. Biologics in Dermatology: Off-Label Indications. Indian Dermatol Online J. 2020;11(3):319–327. doi: 10.4103/idoj.IDOJ_407_18Mpofu S, Fatima F, Moots RJ. Anti-TNF-α therapies: They are all the same (aren’t they?). Rheumatology. 2005;44(3):271–273. doi: 10.1093/rheumatology/keh483Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors. Front Immunol. 2020;11:312. doi: 10.3389/fimmu.2020.00312Hodi FS, Soiffer RJ. Interleukins. In: Encyclopedia of Cancer. 2nd ed. Academic Press; 2002. P. 523–35. doi: 10.1016/B0-12-227555-1/00110-6Sehgal VN, Pandhi D, Khurana A. Biologics in dermatology: An integrated review. Indian J Dermatol. 2014;59(5):425–441. doi: 10.4103/0019-5154.139859Gonçalves F, Freitas E, Torres T. Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs Context. 2021;10:2021-1-7. doi: 10.7573/DIC.2021-1-7Yang K, Oak ASW, Elewski BE. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol. 2021;22(2):173–192. doi: 10.1007/s40257-020-00578-0Batta S, Khan R, Zaayman M, Limmer A, Kivelevitch D, Menter A. IL-17 and -23 Inhibitors for the Treatment of Psoriasis. EMJ Allergy & Immunology. 2023; doi: 10.33590/emjallergyimmunol/10301362Nie T. Spesolimab in generalised pustular psoriasis flares: a profile of its use. Drugs & Therapy Perspectives. 2023;39:404–412. doi: 10.1007/s40267-023-01034-9Курбачева О.М., Галицкая М.А. Место омализумаба в терапии аллергических заболеваний. Медицинский совет. 2019;15:38–49. [Kurbacheva OM, Galitskaya MA. The place of Omalizumab in the treatment of allergic diseases. Meditsinskiy sovet = Medical Council. 2019;15:38–49. (In Russ.)] doi: 10.21518/2079-701x-2019-15-38-49Kara RO, Dikicier BS, Yaldiz M, Koku B, Çosansu NC, Solak B. Omalizumab treatment for chronic spontaneous urticaria: data from Turkey. Postepy Dermatol Alergol. 2022;39(4):704–707. doi: 10.5114/ada.2021.109081Khandelwal K, Jajoo V, Bajpai K, Madke B, Prasad R, Wanjari MB, et al. Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology. Cureus. 2023;15(6):e40734. doi: 10.7759/cureus.40734Кубанов А.А., Абрамова Т.В. Современные методы терапии истинной акатолитической пузырчатки. Вестник дерматологии и венерологии. 2014;90(4):19–27. [Kubanov AА, Abramova TV. Current methods of treatment of true acantholytic pemphigus. Vestnik Dermatologii i Venerologii. 2014;90(4):19–27. (In Russ.)] doi: 10.25208/0042-4609-2014-90-4-19-27Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620–625. doi: 10.1111/j.1365-2133.2005.06651.xTarhini A, Lo E, Minor DR. Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25(6):601–613. doi: 10.1089/cbr.2010.0865Kwok G, Yau TCC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777–89. doi: 10.1080/21645515.2016.1199310Sengupta A. Biological drugs: challenges to access. Penang: Third World Network; 2018. P. 20–5.Soliman M, Oredein O, Dass CR. Update on Safety and Efficacy of HPV Vaccines: Focus on Gardasil. Int J Mol Cell Med. 2021;10(2):101–113. doi: 10.22088/IJMCM.BUMS.10.2.101Heineman TC, Cunningham A, Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019;59:42–48. doi: 10.1016/J.COI.2019.02.009Carvalho T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial. Nat Med. 2023;29(10):2379–2380. doi: 10.1038/d41591-023-00072-0Chocarro-Wrona C, López-Ruiz E, Perán M, Gálvez-Martín P, Marchal JA. Therapeutic strategies for skin regeneration based on biomedical substitutes. J Eur Acad Dermatol Venereol. 2019;33(3):484–496. doi: 10.1111/jdv.15391Cai R, Gimenez-Camino N, Xiao M, Bi S, Divito KA. Technological advances in three-dimensional skin tissue engineering. Reviews on Advanced Materials Science. 2023;62(1):20220289. doi: 10.1515/rams-2022-0289Reijnders CMA, Van Lier A, Roffel S, Kramer D, Scheper RJ, Gibbs S. Development of a Full-Thickness Human Skin Equivalent in Vitro Model Derived from TERT-Immortalized Keratinocytes and Fibroblasts. Tissue Eng Part A. 2015;21(17–18):2448–2459. doi: 10.1089/ten.tea.2015.0139Vidal Yucha SE, Tamamoto KA, Nguyen H, Cairns DM, Kaplan DL. Human Skin Equivalents Demonstrate Need for Neuro-Immuno-Cutaneous System. Adv Biosyst. 2019;3(1):e1800283. doi: 10.1002/adbi.201800283Wong R, Geyer S, Weninger W, Guimberteau JC, Wong JK. The dynamic anatomy and patterning of skin. Exp Dermatol. 2016;25(2):92–98. doi: 10.1111/exd.12832Ковылин Р.С., Алейник Д.А., Федюшкин И.Л. Современные пористые полимерные импланты: получение, свойства, применение. Высокомолекулярные соединения (серия С). 2021;63(1):33–53. [Kovylin RS, Aleinik DA, Fedyushkin IL. Modern porous polymer implants: preparation, properties, application. High molecular weight compounds. 2021;63(1):33–53. (In Russ.)] doi: 10.31857/s2308114721010039Bishop ES, Mostafa S, Pakvasa M, Luu HH, Lee MJ, Wolf JM, et al. 3-D bioprinting technologies in tissue engineering and regenerative medicine: Current and future trends. Genes Dis. 2017;4(4):185–195. doi: 10.1016/J.GENDIS.2017.10.002Bertassoni LE, Cecconi M, Manoharan V, Nikkhah M, Hjortnaes J, Cristino AL, et al. Hydrogel bioprinted microchannel networks for vascularization of tissue engineering constructs. Lab Chip. 2014;14(13):2202–2211. doi: 10.1039/c4lc00030gKang HW, Lee SJ, Ko IK, Kengla C, Yoo JJ, Atala A. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol. 2016;34(3):312–319. doi: 10.1038/nbt.3413Poldervaart MT, Gremmels H, Van Deventer K, Fledderus JO, Öner FC, Verhaar MC, et al. Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture. J Control Release. 2014;184(1):58–66. doi: 10.1016/j.jconrel.2014.04.007Rice JJ, Martino MM, De Laporte L, Tortelli F, Briquez PS, Hubbell JA. Engineering the Regenerative Microenvironment with Biomaterials. Adv Healthc Mater. 2013;2(1):57–71. doi: 10.1002/adhm.201200197Hinton TJ, Jallerat Q, Palchesko RN, Park JH, Grodzicki MS, Shue HJ, et al. Three-dimensional printing of complex biological structures by freeform reversible embedding of suspended hydrogels. Sci Adv. 2015;1(9):e1500758. doi: 10.1126/sciadv.1500758Murphy SV., De Coppi P, Atala A. Opportunities and challenges of translational 3D bioprinting. Nat Biomed Eng. 2020;4(4):370–380. doi: 10.1038/s41551-019-0471-7Nathoo R, Howe N, Cohen G. Skin Substitutes An Overview of the Key Players in Wound Management. Skin substitutes: an overview of the key players in wound management. 2014;7(10):44–48.Cervelli V, Brinci L, Spallone D, Tati E, Palla L, Lucarini L, et al. The use of MatriDerm® and skin grafting in post-traumatic wounds. Int Wound J. 2011;8(4):400–405. doi: 10.1111/j.1742-481X.2011.00806.xZaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf® ) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93–98. doi: 10.2147/ciia.2007.2.1.93Gibson ALF, Holmes JH, Shupp JW, Smith D, Joe V, Carson J, et al. A phase 3, open-label, controlled, randomized, multicenter trial evaluating the efficacy and safety of StrataGraft® construct in patients with deep partial-thickness thermal burns. Burns. 2021;47(5):1024–1037. doi: 10.1016/j.burns.2021.04.021Hart CE, Loewen-Rodriguez A, Lessem J. Dermagraft: Use in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). 2012;1(3):138–141. doi: 10.1089/wound.2011.0282Ehrenreich M, Ruszczak Z. Update on Tissue-Engineered Biological Dressings. Tissue Eng. 2006;12(9):2407–2424. doi: 10.1089/ten.2006.12.2407Мелешина А.В., Быстрова А.В., Роговая О.С., Воротеляк Е.А., Васильев А.В., Загайнова Е.В. Тканеинженерные конструкты кожи и использовние стволовых клеток для создания кожных эквивалентов (обзор). СТМ. 2017;9(1):198–218. [Meleshina AV, Bystrova AS, Rogovaya OS, Vorotelyak EA, Vasiliev AV, Zagaynova EV. Tissue-engineered skin constructs and application of stem cells for creation of skin equivalents (Review). Sovremennye Tehnologii v Medicine. 2017;9(1):198–218. (In Russ.)] doi: 10.17691/stm2017.9.1.24Карамова А.Э., Кубанов А.А., Воротеляк Е.А., Роговая О.С., Чикин В.В., Нефедова М.А., и др. Эффективность живого эквивалента кожи в терапии врожденного буллезного эпидермолиза. Вестник дерматологии и венерологии. 2023;99(6):29–36. [Karamova AE, Kubanov AA, Vorotelyak EA, Rogovaya OS, Chikin VV, Nefedova MA, et al. Efficacy of human living skin equivalent in the treatment of inherited epidermolysis bullosa. Vestnik Dermatologii i Venerologii. 2023;99(6):29–36. (In Russ.)] doi: 10.25208/vdv16249Min JH, Yun IS, Lew DH, Roh TS, Lee WJ. The use of Matriderm and autologous skin graft in the treatment of full thickness skin defects. Arch Plast Surg. 2014;41(4):330–336. doi: 10.5999/aps.2014.41.4.330Waltz E. Cosmetics: when biotech is better than nature. Nat Biotechnol. 2022;40(5):626–628. doi: 10.1038/s41587-022-01318-x